Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC 157 UK: Benefits, Mechanism & Research Guide 2026

BPC 157 UK: Benefits, Mechanism & Research Guide 2026 Quick Answer: BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. In preclinical research, it has been studied for effects o

BPC 157 UK: Benefits, Mechanism & Research Guide 2026

Quick Answer: BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. In preclinical research, it has been studied for effects on tissue repair, tendon healing, angiogenesis, and gastrointestinal protection. It is legal to purchase in the UK for research purposes and is not a controlled substance. It is not approved for human use by the MHRA. Sits inside the tissue-repair cluster of the wider Peptides UK: Research-Grade Sourcing Guide.

What Is BPC-157?

BPC-157 — formally Body Protection Compound 157 — is a pentadecapeptide: a chain of exactly 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of approximately 1,419 Da. It is a synthetic analogue of a segment of the Body Protection Compound protein first isolated from human gastric juice by Professor Predrag Šikirić and his team at the University of Zagreb.

Unlike many research peptides that are fragments of endogenous hormones, BPC-157 has no known endogenous counterpart — it is a sequence selected for its stability and biological activity from within a larger gastric protein. This unusual origin contributes to one of its most important research properties: remarkable stability in human gastric juice, making it resistant to enzymatic degradation in ways that most peptides are not.

The compound has accumulated a substantial body of preclinical literature — over 100 peer-reviewed publications, the majority from Šikirić’s Zagreb laboratory — examining its effects across multiple organ systems in rodent and other animal models. For a deeper overview of its molecular identity, see our guide: What does BPC-157 come from?

How Does BPC-157 Work? Mechanism of Action

BPC-157’s effects in preclinical models appear to operate through several converging pathways rather than a single mechanism. Understanding these pathways is essential for interpreting the research literature accurately.

Angiogenesis via VEGFR2 Upregulation

Perhaps the most consistently documented mechanism is BPC-157’s ability to stimulate angiogenesis — the formation of new blood vessels — by upregulating vascular endothelial growth factor receptor 2 (VEGFR2). In tissue repair, adequate vascularisation is rate-limiting: without new capillary ingrowth, healing tissues are starved of oxygen and nutrients. Multiple animal studies have demonstrated that BPC-157 accelerates capillary growth into wounds and injured tendons, correlating with faster macroscopic healing outcomes (Sikiric et al., Curr Neuropharmacol, 2016; PMID: 26979942).

Nitric Oxide / cGMP Signalling

BPC-157 modulates the nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) signalling pathway. Nitric oxide plays a critical role in vasodilation, cellular signalling, and wound healing. Research in rodent models suggests BPC-157 can both protect against and counteract NO pathway dysregulation — exerting what the literature describes as a “stabilising” effect on NO signalling rather than simply upregulating or downregulating it.

Growth Hormone Receptor Interaction and Tendon Healing

In musculoskeletal research models, BPC-157 has been shown to interact with growth hormone receptor pathways, accelerating tendon-to-bone healing. A key review by Gwyer et al. (Cell Tissue Res, 2019; PMID: 30915550) documented its consistent acceleration of tendon repair across multiple animal models.

FAK-Paxillin Pathway and Cell Migration

At the cellular level, BPC-157 activates the focal adhesion kinase (FAK) — paxillin pathway, which governs cell migration. This is particularly relevant to wound healing, where the rate at which fibroblasts and endothelial cells migrate into the wound bed determines repair speed. For a detailed breakdown: How does BPC-157 work?

BPC-157 Research Areas: What the Preclinical Evidence Covers

Tendon and Ligament Healing

This is the most extensively studied application. Multiple rodent studies have demonstrated statistically significant acceleration of Achilles tendon, rotator cuff tendon, and medial collateral ligament healing with BPC-157 administration. Improvements in tensile strength, histological organisation of collagen fibres, and time to functional research applications have all been documented. The angiogenic and FAK-paxillin mechanisms described above are the proposed drivers. For more detail: Does BPC-157 help tendon healing?

Gastrointestinal Protection

Given its origin in gastric juice, BPC-157’s gastroprotective properties are among its most thoroughly characterised. Sikiric et al. (Curr Pharm Des, 2011; PMID: 21548867) documented its ability to counteract NSAID-induced gastric lesions, protect against ethanol-induced damage, and accelerate healing of established ulcers in rodent models. See also: How does BPC-157 work in promoting gut health?

General Wound Healing and Tissue Repair

Beyond tendons, BPC-157 has been studied in models of skin wound healing, bone repair, corneal injury, and muscle damage. The common thread is acceleration of the proliferative phase of healing — BPC-157-treated animals consistently show faster closure, more organised extracellular matrix, and improved functional research applications vs controls. See: Does BPC-157 heal injuries? and What are the benefits of BPC-157?

Neurological and Brain-Gut Axis Research

A significant portion of the published literature examines BPC-157’s effects on the central nervous system via the brain-gut axis. In rodent models, it has been studied in the context of dopamine and serotonin system modulation, neuroprotection against toxins, and counteraction of withdrawal behaviours. These findings position BPC-157 as a potential research tool for neuro-gastrointestinal axis studies.

Anti-inflammatory Effects

BPC-157 has demonstrated anti-inflammatory properties in animal models, reducing inflammatory markers including NF-κB activation, cyclooxygenase-2 expression, and pro-inflammatory cytokine levels. This is relevant to its healing applications — chronic inflammation is a key impediment to tissue repair, and BPC-157’s ability to modulate this response may underpin many of its observed effects.

BPC-157 Legal Status in the UK (2026)

BPC-157 occupies a specific regulatory position in the UK. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within the scope of the Psychoactive Substances Act 2016. It is not listed on any MHRA prescription-only or pharmacy medicine schedule.

What BPC-157 is not: it is not licensed as a medicine in the UK or EU. The MHRA has not approved it for any clinical indication, and it cannot lawfully be marketed for human consumption, sold as a supplement, or prescribed by a GP. No NHS prescribing pathway exists.

What BPC-157 is: a research chemical that is legal to purchase, possess, and use for legitimate laboratory and scientific research purposes in the UK. Suppliers may sell it with clear “for research use only / not for human consumption” labelling in full compliance with UK regulatory requirements. For the broader picture of peptide law in the UK, see: Are peptides legal in the UK? and the full Buy Research Peptides UK: HPLC, COA & Supplier Due-Diligence Guide.

BPC-157 Forms: Acetate vs Arginate

BPC-157 Acetate

The acetate salt is the most common form in the literature and in commercial supply. It is the form used in the majority of published preclinical studies, making it the standard reference form for researchers wishing to replicate or build on existing findings. Typical lyophilised purity should be ≥98% by HPLC. It is reconstituted with bacteriostatic water or 0.9% acetic acid (the latter can improve stability in solution for some protocols).

BPC-157 Arginate Salt (BPC-157 Stable)

BPC-157 Arginate incorporates an arginine moiety, which is reported to increase aqueous stability and potentially improve oral bioavailability in animal models. The arginate form is of particular interest in gastrointestinal research where oral administration routes are being studied. The trade-off is that the literature base for arginate is thinner than for the acetate form.

BPC-157 vs TB-500: Key Differences for Researchers

Compound type

Synthetic pentadecapeptide (15 AA)

Synthetic analogue of Thymosin Beta-4 (43 AA fragment)

Origin

Derived from human gastric juice protein

Derived from naturally occurring Thymosin Beta-4

Primary mechanism

VEGFR2/angiogenesis, NO/cGMP, FAK-paxillin

Actin polymerisation, cell migration (G-actin sequestration)

Key research areas

Tendon/ligament, gut protection, neurological, wound healing

Muscle repair, cardiac tissue, wound healing, inflammation

Endogenous equivalent

None (no direct endogenous counterpart)

Yes — Thymosin Beta-4 is naturally produced

For a full comparison: BPC-157 vs TB-500: Which Peptide Is Better for Healing? or see the sister pillar TB-500 UK: Mechanism, Actin Biology & Research Guide 2026.

BPC-157 Safety Profile: What the Research Shows

Within the preclinical literature, BPC-157 has a notably clean safety profile. Studies have tested it across oral, subcutaneous, intraperitoneal, and intravenous routes in rodent models without reporting significant toxic effects. No studies have identified a lethal dose in animal models at pharmacologically relevant doses. There are no documented organ toxicity signals in the published literature.

The important caveat: the absence of reported toxicity in animal models does not establish human safety. No completed Phase 2 or Phase 3 clinical trials exist for BPC-157 specifically, meaning extrapolation to human safety profiles is speculative.

For a comprehensive review: Is BPC-157 Safe for Scientific Research? and BPC-157 Side Effects: What Researchers Need to Know

BPC-157 Timeline in Research Models

Angiogenesis initiation: VEGFR2 upregulation and early capillary ingrowth observed within 48–72 hours in wound healing models

Tendon repair acceleration: Statistically significant improvements in healing vs control typically evident by day 7–14 in rodent tendon transection models

Gastric lesion healing: Measurable reductions in ulcer size observed within 24–48 hours in acute rodent models

Functional research applications: Improved strength/function measurements in musculoskeletal models typically at 3–6 weeks vs control

For more detail: When Does BPC-157 Start Working in Tissue Regeneration? and How Long Does BPC-157 Take to Work?

Storage and Reconstitution of BPC-157 for Laboratory Use

Storage Guidelines

Lyophilised powder (unreconstituted): Store at -20°C for long-term stability (up to 24 months). Short-term storage at 2–8°C is acceptable for up to 3 months. Protect from light and humidity.

Reconstituted solution: Store at 2–8°C. Use within 28 days. Do not freeze reconstituted solution. Protect from light.

Reconstitution Protocol

Use bacteriostatic water (sterile water with 0.9% benzyl alcohol) for most laboratory applications

Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the lyophilised powder cake

Swirl gently to dissolve — do not shake or vortex (this can denature the peptide)

Allow to dissolve at room temperature; if residue remains, place in refrigerator for 15 minutes and swirl again

A correctly reconstituted solution should be clear and colourless

For full storage and solubility protocols: BPC-157 Storage and Solubility Tips for Laboratory Use

Sourcing Research-Grade BPC-157 in the UK

The purity and integrity of BPC-157 used in research directly affects the reliability of results. The minimum standards for research-grade BPC-157 are:

Purity ≥98% as verified by HPLC — not just mass spectrometry, which cannot detect closely related impurities

Mass confirmation by LC-MS or MALDI-TOF confirming the correct molecular weight (1,419.53 Da for BPC-157 acetate)

Batch-specific Certificate of Analysis (COA) — a generic COA not linked to the specific production batch is insufficient

Endotoxin testing for in-vivo applications (LAL or equivalent)

Why UK-Dispatched Supply Matters

Peptides are temperature-sensitive. International shipments expose material to potentially uncontrolled temperature excursions during transit. UK-dispatched BPC-157, stored in temperature-controlled conditions and shipped domestically, eliminates cold-chain risk. It also removes import duty and customs delay considerations.

Peptides Lab UK supplies independently HPLC-tested, batch-COA-verified BPC-157 Acetate and BPC-157 Arginate dispatched directly from UK stock. Every batch is tested by an independent third-party laboratory with results available on request. Products are clearly labelled for research use only, in full compliance with UK regulatory requirements.

BPC-157 Supporting Research: The Complete Cluster

What does BPC-157 do?

What type of peptide is BPC-157?

How does BPC-157 work?

What are the benefits of BPC-157?

Does BPC-157 heal injuries?

Does BPC-157 help tendon healing?

Is BPC-157 a Growth Factor?

How Long Does BPC-157 Take to Work?

When Does BPC-157 Start Working in Tissue Regeneration?

BPC-157 Side Effects: What Researchers Need to Know

Is BPC-157 Safe for Scientific Research?

BPC-157 Storage and Solubility Tips for Laboratory Use

How does BPC-157 work in promoting gut health?

BPC-157 vs TB-500: Which Peptide Is Better for Healing?

UK Research Cluster Hubs

BPC-157 sits inside the broader tissue-repair and research-peptide class. For wider UK research context, explore the sister pillars:

TB-500 UK: Mechanism, Actin Biology & Research Guide 2026 — thymosin beta-4 actin biology (the complementary tissue-repair pillar)

Peptides UK: Research-Grade Sourcing Guide — site-wide UK procurement hub

Buy Research Peptides UK: HPLC, COA & Supplier Due-Diligence Guide — how to verify purity and a legitimate UK supplier

GLP-1 Peptides UK: Complete Research Hub 2026 — the incretin metabolic class

Retatrutide UK: Complete Research Guide 2026 — triple GLP-1R/GIPR/GCGR incretin

Tirzepatide UK: Complete Research Guide 2026 — dual GLP-1R/GIPR incretin

Frequently Asked Questions: BPC-157 UK Research

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a sequence of 15 amino acids — derived from a protective protein found in human gastric juice. It is used exclusively in preclinical and laboratory research settings and is not approved for human use by the MHRA.

Is BPC-157 legal in the UK?

BPC-157 is not a controlled substance under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is legal to purchase and possess in the UK for legitimate research purposes. It is not licensed as a medicine by the MHRA and cannot be sold for human consumption.

What does BPC-157 do in research models?

In preclinical research, BPC-157 has been shown to accelerate wound healing, promote tendon and ligament repair, protect gastric mucosa, modulate nitric oxide signalling, stimulate angiogenesis, and exert neuroprotective effects. These findings are from animal studies; no completed human clinical trials exist.

What is the difference between BPC-157 Acetate and BPC-157 Arginate?

BPC-157 Acetate is the most common form, used in the majority of published studies. BPC-157 Arginate incorporates an arginine moiety that is reported to improve aqueous stability and potentially oral bioavailability. The acetate form is the standard for researchers replicating existing literature; the arginate form may be preferred for gastrointestinal oral-route protocols.

What purity should I require for research-grade BPC-157?

A minimum of 98% purity by HPLC, confirmed by a batch-specific Certificate of Analysis. For in-vivo protocols, additionally require endotoxin testing results. Mass spectrometry confirmation of correct molecular weight (1,419.53 Da for acetate) should also be provided.

Source Research-Grade BPC-157 in the UK

Peptides Lab UK supplies independently HPLC-tested, batch-COA-verified BPC-157 Acetate and BPC-157 Arginate dispatched from UK stock. Every product is clearly labelled for research use only, in full compliance with UK regulatory requirements — no prescription required for laboratory purchase. View the verified BPC-157 range at Peptides Lab UK →

For research purposes only / not for human consumption.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157 for research and laboratory use — from £17.99. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

Cookies

By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyse site usage and assist in our tailored marketing efforts.

Cookie Preferences

Strictly Necessary Cookies (Always Active)

These cookies are essential for the website to function and cannot be switched off. They do not store personally identifiable information.

Performance Cookies

These cookies help us analyze traffic and improve performance. All data is aggregated and anonymous.

Functional Cookies

These cookies enable enhanced functionality and personalisation. Disabling may affect certain services.

Targeting Cookies

These cookies may be set by advertising partners to show relevant ads. Disabling will reduce targeted advertising.

Peptides Lab UK

Don't Forget to add

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Reconstitution for Micro-Dosing

Injectable BPC-157 arrives as lyophilized powder requiring reconstitution with bacteriostatic water. For micro-dosing, the concentration you create determines measurement precision. Higher dilutions allow more accurate measurement of small doses. For a 5 mg vial, add 2.5 mL bacteriostatic water to create a 2 mg per mL concentration. At this concentration: 0.05 mL (5 units on insulin syringe) = 0.1 mg dose 0.0625 mL (6.25 units) = 0.125 mg dose 0.075 mL (7.5 units) = 0.15 mg dose Reconstitution technique directly affects peptide integrity. Allow the vial to reach room temperature (15 to 30 minutes) before opening. Disinfect the rubber stopper with alcohol and allow complete evaporation before drawing bacteriostatic water. The critical step involves injecting water along the vial wall rather than directly onto the powder. Angle the needle and slowly allow water to slide down and gently contact the lyophilized material. Vigorous shaking destroys peptide structure through mechanical stress. Gentle swirling or rolling the vial between palms suffices. The peptide typically dissolves within 10 to 20 minutes forming a clear solution. Any cloudiness, discoloration, or persistent particles indicates degradation. Dispose of compromised solutions rather than risking injection of degraded material. Quality peptide properly reconstituted should appear completely clear.
02

Question drills

Open a question for its connected answer.

01What If an Athlete Wants to Use BPC-157 After a Concussion?+

BPC-157 is prohibited by WADA (World Anti-Doping Agency) and NCAA. Any competitive athlete testing positive faces suspension regardless of medical justification. Beyond the regulatory issue, there is no established dosing protocol for TBI, no data on therapeutic window (how soon after injury it must be administered), and no evidence it works in humans at all. Self-administration would be off-label use of a non-FDA-approved compound with unknown safety profile in brain injury contexts. Standard concussion management. Rest, gradual return-to-play protocols, symptom monitoring. Remains the evidence-based approach.

SOURCE / realpeptides.co ↗
02What If I Miss Several Doses During the Protocol?+

Missed BPC-157 doses: the peptide's angiogenic effects are cumulative rather than concentration-dependent, meaning missing 2–3 days delays progress but doesn't negate prior gains. Resume at your standard dose. Don't double-dose to compensate. Missed LL-37 doses have greater immediate impact because antimicrobial activity depends on sustained tissue concentration. A 5–7 day gap allows bacterial regrowth and biofilm reformation. If you miss more than one week of LL-37, consider restarting the pathogen-clearance phase rather than continuing where you left off.

SOURCE / realpeptides.co ↗
03What If the Source Peptide Isn't Sequence-Verified?+

BPC-157 is a specific 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). Substituting even one amino acid alters receptor binding affinity and downstream signaling. Compounded or research-grade peptides should include third-party mass spectrometry verification confirming sequence fidelity and >98% purity. Without this documentation, you're using an uncharacterized compound that may or may not match what was studied in published BPC-157 studied tendon injury trials.

SOURCE / realpeptides.co ↗
04What If Symptoms Persist Weeks After a Concussion — Is BPC-157 Still Useful?+

BPC-157 studied concussion recovery shows diminishing effect size when administered more than 72 hours post-injury in animal models. By the time post-concussion symptoms persist for weeks, the acute inflammatory phase has largely resolved, and the remaining dysfunction reflects chronic changes. Altered neurotransmitter receptor density, disrupted default mode network connectivity, vestibular system impairment. That the peptide's primary mechanisms (microglial modulation, BBB stabilization) don't directly address. That said, the BDNF signaling stabilization effect may still support neuroplasticity during rehabilitation, and anecdotal reports (not clinical data) from peptide research communities suggest subjective cognitive improvement when used alongside vestibular therapy or neurofeedback training.

SOURCE / realpeptides.co ↗
05What If Animal Model Results Don't Translate to Humans — What Are the Known Translation Barriers?+

Species differences in peptide metabolism, receptor density, and pain processing pathways create translation risk. Rodent models of chronic pain measure evoked pain responses (mechanical pressure, thermal stimuli) but cannot capture spontaneous pain, fatigue, or cognitive symptoms central to human fibromyalgia. Pharmacokinetic differences are significant. Peptide half-life, tissue distribution, and blood-brain barrier penetration differ between rodents and humans, potentially requiring dose adjustments that animal data cannot predict. Fibromyalgia's heterogeneity is another barrier. The condition encompasses multiple endotypes (inflammatory-dominant, neuropathic-dominant, central sensitization-dominant) that may respond differently to BPC-157's mechanisms.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

How BPC-157 Is Studied in Research Settings

Scientific exploration of BPC-157 has been limited to controlled laboratory models, including: Cell culture studies Animal-based preclinical investigations Biochemical pathway analysis These studies are designed to observe mechanistic interactions, not real-world outcomes. Findings are typically used to guide further research questions, not conclusions. Researchers emphasize that outcomes observed in laboratory environments do not directly translate beyond controlled experimental conditions.

RESEARCH

Sourcing Research-Grade BPC-157 for Throat Spray Research

For researchers studying oral-mucosal peptide delivery, compound quality directly affects research validity. Research-grade BPC-157 should be verified for purity through HPLC analysis and identity confirmation through mass spectrometry, with batch-specific Certificates of Analysis. Lower-purity material introduces variables that compromise tissue-repair research data. PSPeptides supplies research-grade peptides at 99%+ verified purity with batch-specific third-party HPLC testing and US-based manufacturing. Researchers can explore research-grade BPC-157 in multiple formats at PSPeptides, including oral and injectable research options. The research peptide supplier selection guide covers vendor evaluation, and the peptide purity and COA interpretation guide covers what to verify. The post-Peptide Sciences research peptide market has consolidated around quality-first suppliers as researchers seek reliable sourcing after several major vendor closures. For BPC-157 research, where the tissue-repair endpoints depend on consistent compound quality, verified-purity sourcing is particularly important. Beyond purity verification, sourcing research-grade BPC-157 for throat spray studies benefits from operational reliability — consistent batch quality, transparent Certificates of Analysis, and dependable fulfillment. PSPeptides maintains 99%+ HPLC-verified purity with batch-specific COAs and US-based manufacturing, with free UPS 2nd Day Air shipping on research orders over $200. For BPC-157 throat spray research where tissue-repair endpoints depend on consistent compound quality, this combination of verified purity and reliable supply is a practical research consideration. Researchers can browse the full catalog of BPC-157 research formats and supporting documentation to select the option appropriate to their delivery-route research questions.

POTENTIAL BENEFITS

Gastrointestinal Benefits of BPC 157

มันอาจลดความจำเป็นในการใช้ยาแก้ปวดแบบดั้งเดิมและเสนอทางเลือกที่ปลอดภัยกว่าสำหรับการจัดการความเจ็บปวดในระยะยาว คุณสมบัติในการฟื้นฟูของ BPC-157 เมื่อรวมกับความสามารถในการควบคุมการตอบสนองของภูมิคุ้มกันและรักษาสภาพการทำงานของเซลล์ ทำให้เป็น เปปไทด์ ที่มีประโยชน์หลากหลายพร้อมประโยชน์ต่อสุขภาพมากมาย BPC-157 ได้แสดงให้เห็นประสิทธิภาพที่โดดเด่นในการส่งเสริมการรักษาและปกป้องทางเดินอาหาร มันสามารถช่วยซ่อมแซมความเสียหายของเยื่อบุในกระเพาะอาหารและลำไส้ ซึ่งเสนอประโยชน์ที่อาจเกิดขึ้นสำหรับภาวะต่างๆ เช่น โรคลำไส้อักเสบ (IBD) เช่น ลำไส้ใหญ่อักเสบเป็นแผล และโรคกระเพาะBPC-157 แสดงผลลัพธ์ที่น่าสนใจในการรักษาแผลในกระเพาะอาหาร [4] เพนทาเดคาเปปไทด์ นี้ยังได้รับการพิสูจน์ทางการแพทย์ในหนูว่าสามารถรักษา GI Fistulas ซึ่งเป็นความผิดปกติในระบบย่อยอาหาร
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Syringes Needles Supplies: Comparison

Selecting the right supplies requires understanding the trade-offs between cost, peptide preservation, and protocol complexity. This comparison covers the four most common supply …

Comparison

BPC-157 VEGFR2 Mechanism: Research Comparison

Rat gastric ulcer (Journal of Physiology and Pharmacology, 2020) 10 µg/kg daily, 7 days 2.6-fold increase at Y1175 63% reduction in ulcer area vs 22% control VEGF-A inhibitor (SU5…